Clinical trial
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix
NCT00264732 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 31, 2005
- Completion date
- May 31, 2009
- Enrollment
- 251 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.